Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...
A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...
Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...
Moment of Clarity is pleased to offer TMS treatment. Moment of Clarity highlights Transcranial Magnetic Stimulation (TMS) as a safe, non-invasive treatment for depression, anxiety, and other mental ...
The treatment landscape for multiple myeloma is evolving rapidly, with novel therapies offering renewed hope for patients with relapsed or refractory disease. At this year's American Society of ...
Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...
Multiple sclerosis (MS) is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the ...
Sometimes, the best way to achieve a big outcome is to start small. That principle is at the center of new work from a ...